Biotechnology
Invivoscribe Partners with Complete Genomics to Develop and Commercialize Biomarker Tests for Oncology and Cancer Research
SAN DIEGO and SAN JOSE, Calif., June 2, 2023 /PRNewswire/ -- Invivoscribe and Complete Genomics announced today that they had entered a partnership to develop and commercialize biomarker tests on Complete Genomics' NGS platforms. The territory is worldwide, and the field is oncology and cancer...
2023-06-02 18:00
3178
Innovent Enters into Clinical Trial Collaboration with Merck KGaA, Darmstadt, Germany Investigating Combination Therapy of IBI351 (KRASG12C Inhibitor) and Cetuximab (ERBITUX®)for KRASG12C-mutated NSCLC in China
ROCKVILLE, Md. and SUZHOU, China, June 2, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...
2023-06-02 08:00
5651
Sirnaomics Dosed the First Patient in Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment
HONG KONG, Germantown, Md. and Suzhou, China, June 2, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company"; together with its subsidiaries, the "Group" or "Sirnaomics"; stock code: 2257), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today...
2023-06-02 00:06
6697
YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval From Philippines FDA
GAITHERSBURG, Md., June 1, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseas...
2023-06-01 20:30
2631
CRScube Expands Services in Europe with New Clinical Study Collaborations
SEOUL, South Korea, June 1, 2023 /PRNewswire/ -- CRScube, a leading provider of eClinical solutions, today announced its recent collaborations with two European companies. These new collaborations aim to expand the reach of CRScube's innovative eClinical solutions in the European clinical trial ...
2023-06-01 16:00
2223
Antengene Announces XPOVIO® plus Bortezomib and Dexamethasone Included for Reimbursement by the PBS in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma
- XPOVIO® (selinexor) is the first and only selective inhibitor of nuclear export (SINE) inhibitor approved by the Therapeutic Goods Administration (TGA) ofAustralia for patients with relapsed and/or refractory multiple myeloma (R/R MM) and in triple class refractory R/R MM. - This inclusion b...
2023-06-01 10:09
2964
Brii Biosciences Announces First Subject Dosed in Phase 1 Clinical Trial of BRII-297, Long-Acting Injectable for the Treatment of Anxiety and Depressive Disorders
BRII-297, a first-of-its-kind treatment option for anxiety and depressive
disorders, has the potential to enable greater therapeutic adherence and
convenience for patients
DURHAM, N.C. and BEIJING, June 1, 2023 /PRNewswire/ -- Brii Biosciences
Limited
2023-06-01 08:00
2465
Advances of Qilu Pharmaceutical's QL1706 in Clinical Research Presented at ASCO Annual Meeting
JINAN, China, June 1, 2023 /PRNewswire/ -- The American Society of Clinical Oncology (ASCO) recently announced the selected abstracts for the prestigious ASCO 2023 Annual Meeting. Four clinical research abstracts on QL1706 (iparomlimab/tuvonralimab), an innovative bifunctional antibody for immun...
2023-06-01 00:55
2301
Vazyme Signs Global Strategic Cooperation Agreement with Azenta
NANJING, China, May 31, 2023 /PRNewswire/ -- Vazyme (688105.SH), China's leading biotechnology company, has officially signed a global strategic cooperation agreement with Azenta Life Sciences ("Azenta", Nasdaq: AZTA), which will promote to establish "one-stop" service process for both companies ...
2023-05-31 22:24
4423
Caliway Biopharmaceuticals Announces Initiation of Subject Recruitment in CBL-0204 Phase 2b Study Evaluating the Efficacy of CBL-514 in Abdominal Subcutaneous Fat Reduction
- Caliway has initiated the subject recruitment in CBL-0204 Phase 2b study. - The study is expected to be completed in Q2 2024, and the topline results are anticipated in Q3 2024. TAIPEI, May 31, 2023 /PRNewswire/ -- Caliway Biopharmaceuticals, a biopharmaceutical company focusing on breakthroug...
2023-05-31 20:15
2869
MojiaBio to hold Industrial Biomanufacturing Day following the AIChE Metabolic Engineering Conference in Singapore
SINGAPORE, May 31, 2023 /PRNewswire/ -- Mojia Biotech, a fast-growing biomanufacturing company specializing in the sustainable production of feed additives and bio-based materials, announces that it will hold an Industrial Biomanufacturing Day onJune 15, 2023, following the AIChE Metabolic Eng...
2023-05-31 18:00
3654
SNIPR Biome reports positive clinical interim results for groundbreaking, first-in-human, CRISPR-based microbial gene therapy
* SNIPR001 demonstrates proof of principle in reducing E. coli levels in the human gastrointestinal tract * SNIPR001 is a novel CRISPR-Cas therapeutic, selectively targeting antibiotic-resistant E. coli which can cause life-threatening infections in vulnerable hematological cancer patients ...
2023-05-31 14:58
1723
AffaMed Therapeutics Announces Completion of Patient Enrollment in the Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Cataract Surgery Patients
SHANGHAI, May 31, 2023 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmological, neurological and psychiat...
2023-05-31 11:39
2007
Lynk Pharmaceuticals Completes 200 Million RMB Series C1 Financing to Accelerate Clinical Development of Core Products
HANGZHOU, China, May 31, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, today announced the successful completion of aRMB 200 million Series C1 financing round. There was joint participation by China G...
2023-05-31 08:25
3520
Excellent 12-Month Results from SELUTION SFA Trial Presented at JET
GENEVA, May 31, 2023 /PRNewswire/ -- 12-month results from the SELUTION SFA trial have been presented at the Japan Endovascular Treatment (JET) Conference inTokyo. The objective of this study was to assess the safety and efficacy of SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon, fo...
2023-05-31 08:00
2130
LZ901, A Recombinant Herpes Zoster Vaccine And The Core Product Of Luzhu Biotechnology, Completed Phase II Clinical Trail In Q2 2023
World's First Herpes Zoster Vaccine With A Tetrameric Molecular Structure BEIJING, May 30, 2023 /PRNewswire/ -- Beijing Luzhu Biotechnology Co., Ltd. ("Luzhu Biotechnology" or the "Company", together with its subsidiaries, the "Group", stock code: 02480.HK), a leading vaccine and antibody drug de...
2023-05-30 22:07
2483
Tidetron Shines at Future Food Asia 2023, Securing Award for the Fastest Growing Agrifood Biotech Startup in China
SINGAPORE, May 30, 2023 /PRNewswire/ -- The 7th edition of the Future Food Asia (FFA) conference wrapped up in May, culminating in a resounding triumph for Tidetron Bioworks Technology Co., Ltd. The company's exceptional performance in the Agrifood biotech industry earned them the coveted title o...
2023-05-30 09:00
2389
Concept Medical's fourth IDE approval for the MagicTouch Sirolimus Coated Balloon is granted for the treatment of Superficial Femoral Artery Disease (SFA)
TAMPA, Fla., May 29, 2023 /PRNewswire/ -- The US FDA, on the 24th of May 2023,
granted an Investigational Device Exemption (IDE) approval forConcept Medical
Inc's
2023-05-29 19:40
2909
Hummingbird Bioscience Announces HMBD-002 Trials in Progress Poster at ASCO Annual Meeting 2023
* HMBD-002, a non-depleting, high-affinity anti-VISTA antibody, possesses key design features enabling robust anti-tumor activity in preclinical models, positioning it as a potentially important new therapy for VISTA-expressing cancers including triple-negative breast cancer and non-small cell ...
2023-05-29 18:30
2705
Antengene To Present Latest Results from TORCH-2 Study of ATG-008 in Advanced Solid Tumors in Poster Discussion at ASCO 2023
* The TORCH-2 study is a Phase I/II trial of the mTORC1/2 inhibitor ATG-008 plus the Anti-PD-1 monoclonal antibody toripalimab for the treatment of patients with advanced solid tumors * The combination treatment produced an objective response rate (ORR ) of 52.4% in the advanced cervical canc...
2023-05-26 09:41
2815
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 291 media titles]
2024-04-30 10:11
Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39
Chinese new energy industry contributes to global green, low-carbon transition
[Picked up by 249 media titles]
2024-04-30 15:13New International Land-Sea Trade Corridor achieves rapid development
[Picked up by 246 media titles]
2024-04-28 10:24Most Read
Scienjoy Holding Corporation Reports Fiscal Year 2023 Financial Results
2024-04-27 04:30
2931
